AXIM® Biotechnologies Applies for FDA Emergency Use Approval (EUA) for High Throughput, Patent-Pending Neutralizing Antibody Diagnostic Test for COVID-19

NEXT STORY
Revive Therapeutics Update Following U.S. FDA Approval of Phase 3 Clinical Trial for Bucillamine in COVID-19
PREV STORY
Algernon Announces First Patient Dosed in Phase 2 IPF and Chronic Cough Human Trial of Ifenprodil
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Chembio Diagnostics Announces Completion of U.S. Clinical Trial Evaluating DPP® HIV-Syphilis System

MEDFORD, N.Y., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader ...

author_avatar
NASDAQ Market News

In Vitro Diagnostics (IVD) Market Worth $87.21 Billion by 2024, Growing at a CAGR of 5.7% – Global Opportunity Analysis and Industry Forecasts by Meticulous Research®

author_avatar
NASDAQ Market News

Immutep Quarterly Activities Report

author_avatar
NASDAQ Market News